Please use this identifier to cite or link to this item:
Authors: Duwe, Gregor
Boehm, Katharina
Haack, Maximilian
Sparwasser, Peter
Brandt, Maximilian Peter
Mager, Rene
Tsaur, Igor
Haferkamp, Axel
Höfner, Thomas
Title: Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer : good functional results but oncologically not as safe as expected
Online publication date: 24-Apr-2023
Year of first publication: 2023
Language: english
Abstract: Purpose Focal therapy (FT) for localized prostate cancer (PCa) is only recommended within the context of clinical trials by international guidelines. We aimed to investigate oncological follow-up and safety data of focal high-intensity focused ultrasound (HIFU) treatment. Methods We conducted a single-center prospective study of 29 patients with PCa treated with (focal) HIFU between 2016 and 2021. Inclusion criteria were unilateral PCa detected by mpMRI-US-fusion prostate biopsy and maximum prostate specific antigen (PSA) of 15 ng/ml. Follow-up included mpMRI-US fusion-re-biopsies 12 and 24 months after HIFU. No re-treatment of HIFU was allowed. The primary endpoint was failure-free survival (FFS), defined as freedom from intervention due to cancer progression. Results Median follow-up of all patients was 23 months, median age was 67 years and median preoperative PSA was 6.8 ng/ml. One year after HIFU treatment PCa was still detected in 13/ 29 patients histologically (44.8%). Two years after HIFU another 7/29 patients (24.1%) were diagnosed with PCa. Until now, PCa recurrence was detected in 11/29 patients (37.93%) which represents an FFS rate of 62%.One patient developed local metastatic disease 2 years after focal HIFU. Adverse events (AE) were low with 70% of patients remaining with sufficient erectile function for intercourse and 97% reporting full maintenance of urinary continence. Conclusion HIFU treatment in carefully selected patients is feasible. However, HIFU was oncologically not as safe as expected because of progression rates of 37.93% and risk of progression towards metastatic disease. Thus, we stopped usage of HIFU in our department.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY
Information on rights of use:
Journal: World journal of urology
Version of Record (VoR)
Publisher: Springer
Publisher place: Berlin u.a.
Issue date: 2023
ISSN: 1433-8726
Publisher DOI: 10.1007/s00345-023-04352-9
Appears in collections:DFG-491381577-H

Files in This Item:
  File Description SizeFormat
singlecenter_prospective_phas-20230417152619876.pdf614.81 kBAdobe PDFView/Open